Quick Takeaways:
- Vivesto AB is presenting topline results from its Paccal Vet clinical studies in dogs and cats at the WSAVA World Congress 2026 in Warsaw, Poland, through an oral presentation and an e-poster, expanding the program’s visibility in veterinary oncology.
- The oral presentation shares survival and safety data from a pilot study of Paccal Vet (paclitaxel micellar) in dogs with stage I–II splenic hemangiosarcoma following splenectomy. Recruitment was completed in June 2026, and positive topline results reported in September support progression toward a pivotal study.
- The e-poster presents safety and preliminary antitumor activity data from a dose-escalation study in cats with spontaneous solid tumors, suggesting tolerability and encouraging single-agent activity. Recruitment and maximum tolerated dose determination were completed in July 2026, with final results expected later this year.
Why It Matters?
Vivesto’s Paccal Vet program could expand treatment options in veterinary oncology, an area with significant unmet needs in canine and feline cancer care. Positive preliminary findings across two species support further clinical development, but pivotal-study outcomes and final feline data will be critical to establishing efficacy, safety, and commercial potential against existing treatment approaches.
Source: Vivesto
